{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:06Z","timestamp":1792425726199,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.trecan.2022.01.004","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:49:58Z","timestamp":1645145398000},"page":"397-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Emerging signaling mediators in the anorexia\u2013cachexia syndrome of cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Erin E.","family":"Talbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7276-6609","authenticated-orcid":false,"given":"Denis C.","family":"Guttridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2022.01.004_bb0005","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.trecan.2022.01.004_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.trecan.2022.01.004_bb0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argiles","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2022.01.004_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jamda.2010.02.004","article-title":"Consensus on cachexia definitions","volume":"11","author":"Argiles","year":"2010","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.trecan.2022.01.004_bb0025","first-page":"3347","article-title":"Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer","volume":"45","author":"Evans","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2022.01.004_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pan.2014.11.006","article-title":"Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review","volume":"15","author":"Ozola Zalite","year":"2015","journal-title":"Pancreatology"},{"key":"10.1016\/j.trecan.2022.01.004_bb0035","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1097\/MPA.0000000000000898","article-title":"Predictors of pancreatic cancer-associated weight loss and nutritional interventions","volume":"46","author":"Nemer","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.trecan.2022.01.004_bb0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/SPC.0b013e3283311d09","article-title":"The role of cytokines in cancer cachexia","volume":"3","author":"Argiles","year":"2009","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.trecan.2022.01.004_bb0045","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1200\/JCO.2005.04.2838","article-title":"Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients","volume":"24","author":"Monk","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2022.01.004_bb0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/MPA.0b013e318279b87f","article-title":"Disrupting cytokine signaling in pancreatic cancer: a phase I\/II study of etanercept in combination with gemcitabine in patients with advanced disease","volume":"42","author":"Wu","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.trecan.2022.01.004_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/apm.2018.07.06","article-title":"Anti-cytokines in the treatment of cancer cachexia","volume":"8","author":"Prado","year":"2019","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.trecan.2022.01.004_bb0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","article-title":"Role of interleukin-6 in cachexia: therapeutic implications","volume":"8","author":"Narsale","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.trecan.2022.01.004_bb0065","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.trecan.2022.01.004_bb0070","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2014-4318","article-title":"Role of activin A and myostatin in human cancer cachexia","volume":"100","author":"Loumaye","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.trecan.2022.01.004_bb0075","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","article-title":"GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates","volume":"32","author":"Breen","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.trecan.2022.01.004_bb0080","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-021-22361-3","article-title":"Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia","volume":"12","author":"Olson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2022.01.004_bb0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","article-title":"The MIC-1\/GDF15\u2013GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases","volume":"28","author":"Tsai","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.trecan.2022.01.004_bb0090","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/cells10030516","article-title":"Targeting the activin receptor signaling to counteract the multi-systemic complications of cancer and its treatments","volume":"10","author":"Hulmi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.trecan.2022.01.004_bb0095","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-16-0495","article-title":"Molecular pathways: cachexia signaling \u2013 a targeted approach to cancer treatment","volume":"22","author":"Miyamoto","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2022.01.004_bb0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14728222.2020.1799350","article-title":"Activin A: an emerging target for improving cancer treatment?","volume":"24","author":"Ries","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.trecan.2022.01.004_bb0105","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1210\/en.2019-00257","article-title":"Activin A-induced cachectic wasting is attenuated by systemic delivery of its cognate propeptide in male mice","volume":"160","author":"Walton","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.trecan.2022.01.004_bb0110","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin","volume":"296","author":"Zimmers","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.trecan.2022.01.004_bb0115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.canlet.2014.10.037","article-title":"Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer","volume":"356","author":"Togashi","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2022.01.004_bb0120","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/jcsm.12461","article-title":"The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy","volume":"10","author":"Zhong","year":"2019","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcsm.12033","article-title":"Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients","volume":"6","author":"Lerner","year":"2015","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0130","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.cllc.2019.10.013","article-title":"Elevated circulating activin A levels in patients with malignant pleural mesothelioma are related to cancer cachexia and reduced response to platinum-based chemotherapy","volume":"21","author":"Paajanen","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.trecan.2022.01.004_bb0135","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.3892\/ol.2016.5183","article-title":"Growth differentiating factor-15 (GDF-15): a potential biomarker and therapeutic target for cancer-associated weight loss","volume":"12","author":"Lerner","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.trecan.2022.01.004_bb0140","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.bjc.6605578","article-title":"Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres","volume":"102","author":"Pressoir","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2022.01.004_bb0145","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1017\/S0007114512002073","article-title":"Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy","volume":"109","author":"Sanchez-Lara","year":"2013","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.trecan.2022.01.004_bb0150","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1210\/en.2007-1584","article-title":"The role of activin A and Akt\/GSK signaling in ovarian tumor biology","volume":"149","author":"Do","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.trecan.2022.01.004_bb0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2022.01.004_bb0160","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1158\/0008-5472.CAN-14-0057","article-title":"Myostatin gene inactivation prevents skeletal muscle wasting in cancer","volume":"74","author":"Gallot","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2022.01.004_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","article-title":"Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance","volume":"3","author":"Busquets","year":"2012","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0170","doi-asserted-by":"crossref","first-page":"R716","DOI":"10.1152\/ajpregu.00121.2011","article-title":"Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice","volume":"301","author":"Murphy","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.trecan.2022.01.004_bb0175","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/jcsm.12642","article-title":"ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia","volume":"11","author":"Huot","year":"2020","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022538","article-title":"STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia","volume":"6","author":"Bonetto","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2022.01.004_bb0185","article-title":"Myostatin\/activin receptor ligands in muscle and the development status of attenuating drugs","author":"Rodgers","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.trecan.2022.01.004_bb0190","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jcsm.12331","article-title":"LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial","volume":"9","author":"Golan","year":"2018","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0195","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-19-1065","article-title":"First-in-human phase I study of the activin a inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors","volume":"25","author":"Tao","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2022.01.004_bb0200","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/1471-2407-14-578","article-title":"Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2022.01.004_bb0205","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jcsm.12077","article-title":"MAP3K11\/GDF15 axis is a critical driver of cancer cachexia","volume":"7","author":"Lerner","year":"2016","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0210","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","article-title":"Antibody-mediated inhibition of GDF15\u2013GFRAL activity reverses cancer cachexia in mice","volume":"26","author":"Suriben","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2022.01.004_bb0215","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2022.01.004_bb0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature24042","article-title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15","volume":"550","author":"Hsu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2022.01.004_bb0225","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/nm.4392","article-title":"GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates","volume":"23","author":"Mullican","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2022.01.004_bb0230","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2022.01.004_bb0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbi.2021.07.002","article-title":"Chronic cerebral lipocalin 2 exposure elicits hippocampal neuronal dysfunction and cognitive impairment","volume":"97","author":"Olson","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.trecan.2022.01.004_bb0240","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature21697","article-title":"MC4R-dependent suppression of appetite by bone-derived lipocalin 2","volume":"543","author":"Mosialou","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2022.01.004_bb0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13539-011-0039-1","article-title":"The orally active melanocortin-4 receptor antagonist BL-6020\/979: a promising candidate for the treatment of cancer cachexia","volume":"2","author":"Dallmann","year":"2011","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0250","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1172\/JCI138392","article-title":"Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia","volume":"130","author":"Zhu","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2022.01.004_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101206","article-title":"The melanocortin pathway and energy homeostasis: From discovery to obesity therapy","volume":"48","author":"Yeo","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.trecan.2022.01.004_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO clinical practice guidelines","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2022.01.004_bb0265","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/jcsm.12251","article-title":"Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients","volume":"9","author":"Talbert","year":"2018","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.trecan.2022.01.004_bb0270","first-page":"921","article-title":"Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice","volume":"55","author":"Yasumoto","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2022.01.004_bb0275","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1535-7163.MCT-16-0337","article-title":"Dual inhibition of MEK and PI3K\/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities","volume":"16","author":"Talbert","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2022.01.004_bb0280","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ijc.2910610416","article-title":"Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma","volume":"61","author":"Fujimoto-Ouchi","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2022.01.004_bb0285","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0303-7207(98)00105-1","article-title":"Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice","volume":"142","author":"Llovera","year":"1998","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.trecan.2022.01.004_bb0290","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41598-017-02347-2","article-title":"Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2022.01.004_bb0295","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1158\/0008-5472.CAN-15-3152","article-title":"Differential effects of IL6 and activin A in the development of cancer-associated cachexia","volume":"76","author":"Chen","year":"2016","journal-title":"Cancer Res."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803322000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803322000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:55:23Z","timestamp":1762505723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803322000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2405803322000103"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2022.01.004","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging signaling mediators in the anorexia\u2013cachexia syndrome of cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2022.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}